The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Bipolar disorder is a complex psychiatric disorder, characterized by fluctuations between episodes of (hypo)mania and ...

Many Canadians struggle with SAD, a real form of depression that can make navigating the winter months extremely difficult.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Seasonal affective disorder (SAD) is a type of recurrent depressive periods that occur during the same season each year. SAD ...

As winter weather keeps many of us indoors and icy roads limit our activities, it’s easy to start feeling a little off.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...